

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
M. Kröz <i>et al.</i>	)	Art Unit: 1646
	)	
Application No. 10/584,438	)	Examiner: Dong Jiang
	)	
Filing Date: January 29, 2008		
(International Filing Date: 12/03/2004)	)	Confirmation No. 2609
	)	
For: INTERLEUKIN-11 FUSION PROTEINS	)	

**RESPONSE TO RESTRICTION REQUIREMENT**

Mail Stop Amendment	BALLARD SPAHR ANDREWS &
Commissioner for Patents	INGERSOLL, LLP
P.O. Box 1450	
Alexandria, VA 22313-1450	Customer Number 23859

Sir:


In response to the Requirement for Restriction dated February 6, 2009, Applicants elect to prosecute the claims of Group III, that is, claims 25-29, 32 and 33 drawn to a method of treatment with an albumin-fused IL-11. With regard to this group, Applicants further elect to prosecute species (1) drawn to minimizing a side effect associated with IL-11 treatment. Claims 25, 26, 28, 29 and 33 are readable on the elected species. Applicants confirm their right to file divisional applications that include the non-elected claims.

A favorable action on the merits is requested respectfully.


ATTORNEY DOCKET NO. 16238.0002U1  
APPLICATION NO. 10/584,438

Respectfully submitted,

BALLARD SPAHR ANDREWS &  
INGERSOLL, LLP

  
Marc S. Segal  
Registration No. 40,163

BALLARD SPAHR ANDREWS &  
INGERSOLL, LLP  
Customer Number 23859  
(215) 864-8843  
(678) 420-9301 (fax)

CERTIFICATE OF ELECTRONIC TRANSMISSION UNDER 37 C.F.R. § 1.8			
I hereby certify that this correspondence, including any items indicated as attached or included, is being transmitted via electronic transmission via EFS-Web on the date indicated below.			
Name of Person Mailing (Print/Type)	Marc S. Segal		
Signature		Date	3/5/2009